SecBot SecBot
8-K ·Filed Jul 24, 2026

NAMS

NewAmsterdam Pharma Co N.V.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-315163
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The positive CHMP opinion is a major derisking event for European approval. Traders should watch for the EC decision in 2H26 as the next catalyst. The PREVAIL cardiovascular outcomes trial readout will be the next major binary event for U.S. approval prospects. The stock is likely to re-rate on this regulatory progress.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$29.64
T+0 close · Jul 24, 2026 · via day close
Latest settled
−30.94%
T+60 · $20.47
Vs SPY
−34.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 24 $29.64entry
  2. T+1 · 4mo ago +1.96%α +1.94% · $30.22
  3. T+5 · 4mo ago −3.98%α −4.35% · $28.46
  4. T+20 · 3mo ago −5.97%α −9.60% · $27.87
  5. T+60 · 29d ago −30.94%α −34.23% · $20.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe. The European Commission is expected to issue a final decision in 2H26, and if approved, this would enable commercialization of obicetrapib across EU member states, Iceland, Liechtenstein, and Norway, unlocking milestone payments of up to €833 million for NewAmsterdam plus tiered double-digit royalties on net sales in the Menarini territory.

Key Facts

  • CHMP adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination).
  • Recommendation is supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing up to ~40% LDL-C reduction with obicetrapib monotherapy and ~50% with the combination vs placebo.
  • European Commission decision expected in 2H26; if granted, authorization applies across all EU member states plus Iceland, Liechtenstein, and Norway.
  • NewAmsterdam is entitled to up to €833 million in clinical, regulatory, and commercial milestones plus tiered double-digit royalties (low double-digits to mid-twenties) on net sales in the Menarini territory.
  • Menarini holds exclusive commercialization rights for obicetrapib in Europe and is responsible for regulatory interactions and commercialization.

Financial Impact

Up to €833 million in milestone payments plus tiered double-digit percentage royalties on European net sales

milestone revenueroyalty revenue

Risk Factors

  • EC may not grant final marketing authorization despite CHMP positive opinion
  • Commercial uptake in Europe depends on pricing and reimbursement negotiations
  • PREVAIL cardiovascular outcomes trial results remain a key binary risk for full commercial potential

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-315163
Document: nams-ex99_1.htm0001193125-26-315163
Document: 0001193125-26-315163-index-headers.html0001193125-26-315163
Document: 0001193125-26-315163-index.html0001193125-26-315163
Document: 0001193125-26-315163.txt0001193125-26-315163

Track record

8 reports on NAMS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +7.23% at T+5 after the Sep 22, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.89 to $18.90 Now $19.46 +3.02% ▲ +0.05% −0.26% vs SPY
  2. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $20.93 to $18.89 Now $19.46 −7.02% ▼ −9.75% −5.34% vs SPY
  3. Sep 29, 20266w ago 8-K Neutral 4/10 Entry $23.81 to $24.32 Now $19.46 −18.27% ▲ +2.14% +2.35% vs SPY
  4. Sep 22, 20267w ago SC 13D/A Bullish 5/10 Entry $22.68 to $22.74 Now $19.46 −14.20% ▲ +0.26% +0.35% vs SPY
  5. Sep 15, 20268w ago Insider Buy Bullish 5/10 Entry $21.18 to $21.93 Now $19.46 −8.12% ▲ +3.54% +2.41% vs SPY
  6. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $27.42 to $27.67 Now $19.46 −29.03% ▲ +0.91% +1.07% vs SPY
  7. Jul 24, 202616w ago 8-K Bullish 7/10 Viewing Entry $29.64 to $30.22 Now $19.46 −34.35% ▲ +1.96% +1.94% vs SPY
  8. Apr 8, 202631w ago Press Release Neutral 5/10 Entry $34.01 to $35.07 Now $19.46 −42.78% ▲ +3.12% +2.54% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026